TAL6 Immunopeptides for Targeted Cancer Therapy
Solution Overview
Problem
Current cancer therapies lack effective targeting of tumor-associated antigen L6 (TAL6) expressed on various cancer cells, limiting the efficacy of cancer immunotherapy.
Innovation Solution
Development of isolated immunopeptides containing T-cell epitopes from TAL6, specifically restricted to HLA-A2 or HLA-A24, which can be used to stimulate immune responses and inhibit tumor growth, combined with a pharmaceutically acceptable carrier and adjuvant for enhanced immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies are used, then general treatment is provided, but effective targeting of tumor-associated antigen L6 is lacking
Solution Approach 1:
The patent segments the tumor-associated antigen L6 into specific peptide epitopes (e.g., CIGHSLVGL, SLVGLALLC, ALLCIAANI) that can be individually recognized by T-cells. This segmentation allows the vaccine to target specific antigenic regions rather than requiring recognition of the entire antigen, thereby improving targeting efficacy while maintaining adaptability across different HLA types.
Solution Approach 2:
The patent applies local quality by designing peptides with specific HLA restriction patterns (HLA-A2, HLA-A24) that match particular patient populations. Each peptide is optimized to bind to specific HLA molecules, creating localized immune responses tailored to the patient's HLA profile, thus improving both targeting efficacy and adaptability.
2Reliability
If cancer immunotherapy is used, then immune response is stimulated, but efficacy is limited without effective antigen targeting
Solution Approach 1:
By segmenting L6 into discrete peptide epitopes, the patent simplifies vaccine manufacturing compared to using whole antigen proteins. The peptides can be synthesized chemically with high purity and consistency, avoiding the complexity of protein expression, purification, and quality control associated with whole protein vaccines, thereby improving ease of manufacture while maintaining immune response efficacy.
Solution Approach 2:
The patent changes the physical-chemical parameters of the antigen from whole protein to small peptides, which improves manufacturability through chemical synthesis. This parameter change also allows for precise control of peptide sequence, purity, and HLA binding affinity, thereby enhancing both ease of manufacture and immune response efficacy.
3Reliability
If CTL epitope-based cancer vaccine is developed, then cytotoxicity responses are induced, but identification of appropriate epitopes is essential and complex
Solution Approach 1:
The patent segments the L6 antigen into multiple overlapping peptide fragments and systematically tests them for HLA binding and T-cell recognition. This segmentation approach converts the complex problem of whole-antigen epitope identification into a manageable library of small peptides, reducing the complexity of epitope identification while ensuring reliable tumor cell elimination through CTL induction.
Solution Approach 2:
The patent identifies peptides that can bind to multiple HLA alleles (e.g., HLA-A2, HLA-A24) and stimulates broad T-cell responses. This universality approach allows a single vaccine formulation to potentially treat patients with different HLA types, reducing the complexity of personalized epitope selection while maintaining reliable tumor cell elimination.
Data Source
AI summary
An immunopeptide containing a T cell epitope from the tumor associated antigen L6 (TAL6) and a nucleic acid encoding the immunopeptide are described herein. The immunopeptide or its encoding nucleic acid can be used as a component of an immune composition for enhancing immune response against cancer cells that express TAL6.